Barış, V. Ö. Et Al. 2021. Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways.. Cardiovascular toxicology , vol.21, no.9 , 747-758.

Barış, V. Ö., Dinçsoy, A. B., Gedikli, E., Zırh, S., MÜFTÜOĞLU, S. F., & ERDEM, A., (2021). Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways.. Cardiovascular toxicology , vol.21, no.9, 747-758.

Barış, Veysel Et Al. "Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways.," Cardiovascular toxicology , vol.21, no.9, 747-758, 2021

Barış, Veysel Ö. Et Al. "Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways.." Cardiovascular toxicology , vol.21, no.9, pp.747-758, 2021

Barış, V. Ö. Et Al. (2021) . "Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways.." Cardiovascular toxicology , vol.21, no.9, pp.747-758.

@article{article, author={Veysel Özgür Barış Et Al. }, title={Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways.}, journal={Cardiovascular toxicology}, year=2021, pages={747-758} }